



DECEMBER 2020

## KMAP GENERAL BULLETIN 20245

### Prothrombin Time (PT/INR) Monitoring for Home Anticoagulation Management

Effective with dates of service on and after January 1, 2021, the use of home Prothrombin Time/International Normalized Ratio (PT/INR) monitoring for chronic, oral anticoagulation management for patients with mechanical heart valves, chronic atrial fibrillation, or venous thromboembolism (inclusive of deep venous thrombosis and pulmonary embolism) on coumadin (Warfarin) will be covered. The monitor and the home testing must be prescribed by a treating physician as provided in 42 CFR 410.32(a) and all the following requirements must be met:

1. The patient must have been anticoagulated for at least 3 months prior to use of the home INR device; and,
2. The patient must undergo a face-to-face educational program on anticoagulation management and must have demonstrated the correct use of the device prior to its use in the home; and,
3. The patient continues to correctly use the device in the context of the management of the anticoagulation therapy following the initiation of home monitoring; and,
4. Self-testing with the device should not occur more frequently than once a week.

Applicable Health Care Common Procedure Coding System (HCPCS) Codes G0248, G0249, and G0250 will be used for claims processing.

**Note:** The effective date of the policy is January 1, 2021, the implementation of State policy by the KanCare managed care organizations (MCOs) may vary from the date noted in the Kansas Medical Assistance Program (KMAP) bulletins. The KanCare Open Claims Resolution Log on the KMAP [Bulletins](#) page documents the MCO system status for policy implementation and any associated reprocessing completion dates, once the policy is implemented.

#### KMAP

[Kansas Medical Assistance Program](#)

- [Bulletins](#)
- [Manuals](#)
- [Forms](#)

#### Customer Service

- 1-800-933-6593
- 7:30 a.m. - 5:30 p.m.  
Monday - Friday

Gainwell Technologies is the fiscal agent of KMAP.